VNN1 and metabolic dysfunction-associated steatohepatitis: The uptake of EVs was, partly, dependent on vanin-1 expression on the EV surface, with vanin-1-neutralizing antibodies leading to a decreased HSC activation in vitro and exemplifying the therapeutic potential of targeting EVs in the treatment of NASH [38] (Figure 2).